2022
Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials
Shoji S, Kohsaka S, Shiraishi Y, Kohno T, Sawano M, Ikemura N, Niimi N, Nagatomo Y, Tanaka T, Takei M, Ono T, Sakamoto M, Nakano S, Nakamura I, Inoue S, Fukuda K, Yoshikawa T. Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials. International Journal Of Cardiology 2022, 359: 76-83. PMID: 35421518, DOI: 10.1016/j.ijcard.2022.04.020.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsHeart FailureHumansStroke VolumeConceptsConventional medical therapyHF readmission ratesMedical therapy useMedical therapyLong-term outcomesEnrollment criteriaReadmission ratesTherapy useRecent trialsReduced ejection fractionHeart failure patientsHeart failure treatmentUse of BBsShift trialsDAPA-HFHF registryHFrEF patientsMulticenter registryPARADIGM-HFFailure patientsConsecutive patientsEjection fractionPatient subsetsPrescription ratesFailure treatment
2020
Guideline-Based Medications for Older Adults Discharged after Percutaneous Coronary Intervention in a Suburban City of Japan: A Cohort Study Using Claims Data
Shimada K, Hamada S, Sawano M, Yamamoto H, Yoshie S, Iijima K, Miyata H. Guideline-Based Medications for Older Adults Discharged after Percutaneous Coronary Intervention in a Suburban City of Japan: A Cohort Study Using Claims Data. The Tohoku Journal Of Experimental Medicine 2020, 252: 143-152. PMID: 33028759, DOI: 10.1620/tjem.252.143.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsFemaleGeriatricsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInsurance Claim ReviewJapanMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionOdds RatioPatient DischargePercutaneous Coronary InterventionPractice Guidelines as TopicRetrospective StudiesSecondary PreventionConceptsPercutaneous coronary interventionGuideline-based medicationsSecondary preventionΒ-blockersCohort studyCoronary interventionPrescription ratesClaims dataMultivariable logistic regression analysisOlder groupOlder adultsPrescription of antiplateletACEI/ARBRetrospective cohort studyAssociation of ageLogistic regression analysisCardiovascular eventsReceptor blockersAdjusted analysisBetter prognosisEnzyme inhibitorsMedicationsCommunity settingsStatinsPrevention